drugset
drugset / Trial / NCT07385079

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

NCT07385079 ↗

Phase 3 Not yet recruiting 412 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial aimed to evaluate the efficacy of anlotinib hydrochloride combined with benmelstobart, induction chemotherapy, and concurrent chemoradiotherapy (IC+CCRT), versus a regimen of benmelstobart plus IC+CCRT, in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (LANPC).

Timeline

Start
2026-03-01
Primary completion
2028-01-01
Completion
2030-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 10 mg —
Background Benmelstobart Monoclonal antibody 1200 mg —
Background Cisplatin Other / unclassified 100 mg/m2 —
Background Gemcitabine Small molecule 1 g —

Indications

nasopharyngeal carcinoma